Procept Biorobotics Corp (PRCT) Q4 2025 Earnings Call Transcript

Why It Matters

The accelerated top‑line growth and margin expansion put Procept on a clearer path to profitability, while new leadership and product launches position it for broader market penetration in urology.

Key Takeaways

• Revenue up 48% YoY to $79.2M.
• Gross margin reached 65.4%, up 640 basis points.
• Adjusted EBITDA loss narrowed to $8M year‑to‑date.
• Guidance lifted: $325.5M revenue, 53k handpieces.
• Larry Wood becomes CEO; CCO role eliminated.

Pulse Analysis

Procept Biorobotics’ Q2 2025 results underscore a rapid scaling phase that outpaces many peers in the minimally invasive urology space. Revenue surged nearly half, propelled by a 46% rise in U.S. sales and a 58% jump in handpiece and consumable revenue, indicating robust adoption of its aquablation technology. The margin uplift to 65.4%—driven by higher average selling prices and disciplined cost control—narrows the adjusted EBITDA gap, suggesting the company is edging toward breakeven as fourth‑quarter volumes materialize. Investors will watch whether the raised full‑year outlook, now forecasting $325.5 million in revenue, holds as the sales funnel for the Hydros platform fills.

The product narrative is equally compelling. The newly launched Hydros robotic system, featuring AI‑assisted functions and single‑use components, has garnered positive early feedback, reinforcing Procept’s push to modernize urologic surgery. Handpiece shipments climbed 59% year‑over‑year, and the Waterfort trial is on track for full enrollment by 2026, with same‑day prostate‑cancer procedures already demonstrated in an ASC setting. These clinical milestones, combined with expanding relationships across 17 major integrated delivery networks, broaden the addressable market and lay groundwork for replacement‑system sales that could become a primary growth engine post‑2026.

Strategic leadership changes round out the outlook. Incoming CEO Larry Wood, a veteran of Edwards Lifesciences’ TAVR business, brings extensive device‑scale experience just as Procept restructures its commercial organization, eliminating the CCO role and creating senior sales and marketing positions reporting directly to the CEO. Concurrently, tariff exposure has been trimmed to $1‑2 million after Chinese duties fell, and Medicare’s proposed 5.6% facility‑fee increase further supports procedural economics. Together, these factors enhance confidence that Procept can sustain its growth trajectory while moving toward profitability, a narrative likely to resonate with growth‑oriented investors.